Search:
Filter:
Post type:
Sort:
United States District CourtSouthern District of Virginia USA v John Thomas Howard Criminal Complaint Filed October 2026 Read the complaint and affidavit
Paige Gordon asked her med spa about a peptide treatment. No one reviewed her health history or talked about potential risks. Months later, her cancer came back.
Paige Gordon bought a peptide promising glowing skin on the recommendation of a licensed nurse she’d been a patient of for years at a med spa. Two months ago, she was told her cancer returned.
The policy effectively allows compounders to produce these drugs, which are massively understudied, even though they don’t meet federal criteria for compounding.
“Today’s decision leaves Americans in a grey area as to whether peptides are safe or not, even though the FDA’s own scientists recommended against voting in favor of these substances due to concerns with evidence.”
The peptides in question are untested and poorly defined, and making them easier to compound is a threat to public safety.
Eli Lilly filed a complaint against InstantRx and other defendants that allegedly distributed counterfeit and/or misbranded versions of Lilly-branded medicines through online pharmacy to pharmacy marketplaces.
Two deaths have been linked to black market versions of retatrutide, as a British woman warns followers that taking an early dose of the drug “nearly killed” her.
The Partnership for Safe Medicines (PSM) filed a citizen petition urging the U.S. Food and Drug Administration to block compounding of unapproved peptides and to disregard the advisory committee vote that recommended allowing them.
PSM submits comment opposing HHS’s proposed peptide enforcement discretion policy
The policy would expose patients to unproven substances that FDA’s career staff recommended not be used in compounding because of safety and other concerns.
Read More about PSM submits comment opposing HHS’s proposed peptide enforcement discretion policy